HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects

BACKGROUND: Pertuzumab is a humanized monoclonal antibody for the treatment of breast cancer. HLX11 is a biosimilar of pertuzumab developed by Shanghai Henlius Biotech, Inc. We conducted a bioequivalence study for HLX11 and pertuzumab (United States [US]-, European Union [EU]-, and China [CN]-approv...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jingjing, Lin, Lili, Long, Qihe, Zhang, Qian, Sun, Guilan, Zhou, Liang, Wang, Qingyu, Zhu, Jun, Li, Fanfan, Hu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148872/
https://www.ncbi.nlm.nih.gov/pubmed/35594017
http://dx.doi.org/10.1007/s40259-022-00534-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9148872/
https://www.ncbi.nlm.nih.gov/pubmed/35594017
http://dx.doi.org/10.1007/s40259-022-00534-w

Ejemplares similares